Early Monitoring Drug Resistant Mutation T790M with a Two-Dimensional Simultaneous Discrimination Nanopore Strategy

Anal Chem. 2020 Jul 7;92(13):8867-8873. doi: 10.1021/acs.analchem.0c00575. Epub 2020 Jun 8.

Abstract

With the aim of detecting low frequency of drug resistant mutation T790M against wild-type sequences, we reported a two-dimensional signal analysis strategy by combining a three locked nucleic acids (LNAs)-modified probe (LP15-3t) and an α-HL nanopore. The specific hybridization of the LP15-3t probe with the T790M generated unique long two-level signals, including characteristic blocking current and characteristic dwell time. Due to the significant dwell time difference (114.2-fold) and the blocking current difference ranging from 81% to 96%, this two-dimensional signal analysis strategy can simultaneously distinguish T790M sequences with a sensitivity of 0.0001% against wild-type sequences. The LOD of T790M was 0.1 pM. This high discrimination capability would have great potential in the detection of rare mutation sequences and the early monitoring of clinical outcome of NSCLC patients with TKI drug resistance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Discriminant Analysis
  • Drug Resistance, Neoplasm / genetics*
  • ErbB Receptors / blood*
  • ErbB Receptors / genetics
  • Humans
  • Limit of Detection
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / genetics
  • Lung Neoplasms / pathology
  • Mutation
  • Nanopores*
  • Neoplastic Stem Cells / metabolism
  • Oligonucleotides / chemistry*
  • Oligonucleotides / metabolism
  • Polymerase Chain Reaction
  • Protein Kinase Inhibitors / therapeutic use

Substances

  • Oligonucleotides
  • Protein Kinase Inhibitors
  • locked nucleic acid
  • ErbB Receptors